Category: Heme/Onc

Clinical Correlations


Cancer Survivors – Who are they, what are their needs, and how can medical providers meet these needs?

By Maria Garcia-Jimenez, MD/MHS, Abinav Baweja, MD, and Nicole LaNatra, MD

Peer Reviewed

Clinical vignette

A 65-year old woman with history of invasive breast cancer presents to her primary care provider for regular follow up. She was diagnosed with breast cancer over 10 years ago and received chemotherapy, radiation, and hormonal therapy with aromatase inhibitors.…

Read More

Sex or Drugs: Why Do We See An Increased Incidence of Oropharyngeal Cancer?

Tonsils&Throat_Anatomy2By Tyler Litton, MD

Peer Reviewed

Oropharyngeal squamous cell carcinoma (OPSCC) is relatively rare but incidence has increased in the US over the past 40 years. [1] Tonsillar cancer is the most common type of OPSCC followed by base of tongue cancer, which together account for 90% of all OPSCCs.[2] The incidence of both tonsillar and base of tongue cancers individually have also increased in the US.[3] OPSCC is more common in men than women and smoking and alcohol are well known risk factors for it.[1,4] However, the increased incidence in the US has not seen a parallel rise in smoking and alcohol consumption.[5] This implies some other factor may be responsible for epidemiologic changes in OPSCC rates.…

Read More

Shifting Paradigms in Cancer: Vaccines

Joshua Horton

Peer Reviewed

We are not winning the war against cancer, if war is even an appropriate metaphor. When Richard Nixon signed the National Cancer Act into effect in 1971, many predicted that cancer would be a thing of the past within 5 years.…

Read More

Lung Cancer Screening with Low-Dose CT Scans

By Susanna Jeurling

Peer Reviewed

The U.S. Preventive Services Task Force (USPSTF) recently finalized its position regarding annual low-dose computed tomography (LDCT) scanning for early detection of lung cancer. The grade B recommendation states that individuals between the ages of 55 and 80 with a 30 pack-year history or more of smoking who are current smokers or who have quit within the last 15 years should undergo annual LDCT screening, based on the results of the National Lung Screening Trial [1].…

Read More

From The Archives: Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism?

Please enjoy this post from the archives dated September 8, 2011

By David Altszuler, Class of 2012

Faculty Peer Reviewed

An empiric association between occult malignancy and thrombophlebitis has been recognized since Trousseau first reported the syndrome in 1865.[1] The mechanism by which cancer predisposes to thrombophilia has not been fully elucidated; however, it is now clear that this is a symbiotic relationship.[2] The second leading cause of death in hospitalized cancer patients (and a leading cause of death in ambulatory cancer patients) is venous thromboembolism.[3] There are algorithms to identify cancer patients at high risk for developing venous thromboembolism (VTE), and a recently undertaken clinical trial exploring the efficacy of anticoagulation prophylaxis in these patients will likely establish guidelines for prophylactic treatment in the outpatient setting.…

Read More

An antidote on the horizon? An update on the progress toward achieving reversibility for the new oral anticoagulants

By Gabriel Schneider, MD

Peer Reviewed

The new oral anticoagulants (NOACs) are an appealing alternative to the burdensome vitamin K antagonists such as warfarin. These novel agents include direct thrombin inhibitors such as dabigatran (which inhibits thrombin) and factor Xa inhibitors such as rivaroxaban and apixaban (which prevent thrombin generation).

Read More